March 2022

ENDOCRINOLOGY

NORTHWESTERN INVESTIGATES COVID-19: ANTIBODIES, GLOBAL SURVEILLANCE

 Featuring: Alexis Demonbreun, PhD, William Lowe, Jr., Egon Ozer, MD, PhD , Joseph Feinglass, PhD, Susan Quaggin, MD
​​
As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, including investigating antibody protection against COVID-19 reinfection.

Previous SARS-COV-2 Infection Does Not Guarantee Antibody Protection

​A team of Northwestern Medicine investigators found that among individuals with prior SARS-COV-2 infection, less than half had moderate to high enough levels of antibodies to protect them against reinfection. The findings, published in Open Forum Infectious Diseases, help dispel the myth that natural immunity after SARS-CoV-2 infection is more effective than vaccines in reducing hospitalization or mortality risk, according to the authors.

“These results suggest that prior infection with SARS-CoV-2 does not guarantee a high level of antibody-mediated protection against reinfection,” said Thomas McDade, PhD, professor of Medical Social Sciences and first author of the study.

The investigators measured levels of antibody-mediated neutralization of the spike protein- ACE2 receptor — which allows the SARS-COV-2 virus to infect healthy host cells — in blood samples from participants previously enrolled in the Screening for Coronavirus Antibodies in Neighborhoods (SCAN) study. Participants were recruited to SCAN between June 24, 2020 and November 11, 2020.

Overall, moderate to high levels of SARS-COV-2 protective antibodies were present in less than half of participants who required clinical care — 41.3 percent. Additionally, protective immunity was present in just 7.9 percent of symptomatic infections and 1.9 percent of asymptomatic infections.

“This information may be important for public health messaging to the large and growing proportion of the global population that has been previously infected with SARS-CoV-2 and remains unvaccinated, or only partially vaccinated,” said Alexis Demonbreun, PhD, assistant professor of Pharmacology and senior author of the study.

Co-authors of the study include Richard D’Aquila, MD, the Howard Taylor Ricketts, MD, Professor of Medicine in the Division of Infectious Diseases and associate vice president of research; Brian Mustanski, PhD, professor of Medical Social Sciences, Psychiatry and Behavioral Sciences and director of Impact Institute; and Elizabeth M McNally, MD, PhD, the Elizabeth J. Ward Professor of Genetic Medicine and director of the Center for Genetic Medicine.

D’Aquila and Mustanski are members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This work was funded by the National Science Foundation grant 2035114, the National Institutes of Health grant 3UL1TR001422-06S4 and Northwestern University’s Office of Research.

Continuing Global Surveillance of SARS-CoV-2 Variants  
​
​​An international team of investigators found that the SARS-CoV-2 variant A.27, which was first identified in Germany in spring 2021, successfully evades currently available monoclonal antibody treatments.

The findings, published in Nature Communications, emphasize the need for continued global monitoring of new SARS-COV-2 variant strains, as they continually demonstrate the ability to evade current therapeutic regimens.

From phylogenetic analysis of SARS-CoV-2 genome sequence data obtained from the Robert Koch Institute in Germany, the investigators detected the presence of A.27 in 31 countries from December 2020 to June 2021, and determined it likely stemmed from separate introduction events out of Western Africa.

“Thanks to our research collaborators in Nigeria, we were able to sequence examples of these viruses from samples collected from patients in Nigeria in January and February of 2021, suggesting this lineage may have arisen in Western Africa,” said Egon Ozer, MD, PhD, ’08 GME, assistant professor of Medicine in the Division of Infectious Diseases, director of the Center for Pathogen Genomics and Microbial Evolution and a co-author of the study.

They also found that A.27 has a specific mutation in the SARS-CoV-2 spike protein, which allows the virus to infect healthy host cells. The investigators also demonstrated that A.27 is less susceptible to SARS-CoV-2-specific antibodies and that current COVID-19 vaccines and treatments may not fully protect patients against the infection.

“The presence of concerning S mutations in an A-derived lineage supports the notion that the same escape mutations can appear in relatively distant genomic backgrounds with similar phenotypic consequences. Therefore, global molecular surveillance has to continue to detect novel variants and to support assessing their risk for the human population,” the authors wrote.

The Art of Nephrology During COVID-19​

​In a recent editorial published by the American Society of Nephrology (ASN), Susan Quaggin, MD, chief and the Charles H. Mayo, MD, Professor of Medicine in the Division of Nephrology and Hypertension and president of ASN, reflected on the impact COVID-19 has had on the field of nephrology while also applauding the field’s leadership, innovation, research advances and commitment to patient care and advocacy.

“We have witnessed firsthand the major impact of the acute infection and long-term complications from COVID-19 on kidney health. We also understand the increased kidney disease burden that the world will surely face in the coming years,” wrote Quaggin, who is also director of the Feinberg Cardiovascular and Renal Research Institute.

Quaggin wrote that the field should learn from the COVID-19 pandemic to transform and advance all aspects of nephrology, and noted two ways that the field is already improving: by prioritizing kidney health and disease prevention and committing to healthcare justice and access.

“Let us continue to leverage these advances and build on what we’ve learned during the past two years,” Quaggin wrote. “Responding successfully to major crises and being visionary at our core: these efforts represent the art of nephrology.”

​
This article  is modified from one originally published in the Northwestern University Feinberg School of Medicine News Center on March 28, 2022. 
Alexis Demonbreun, PhD, assistant professor of Pharmacology, was senior author of the study published in Open Forum Infectious Diseases.
William Lowe, Jr., MD, the Thomas D. Spies Professor of Genetic Metabolism and a professor of Medicine in the Division of Endocrinology, Metabolism and Molecular Medicine, was a co-author of the editorial published in Nature Medicine.
Egon Ozer, MD, PhD, ’08 GME, assistant professor of Medicine in the Division of Infectious Diseases and director of the Center for Pathogen Genomics and Microbial Evolution, was a co-author of the study published in Nature Communications.
Susan Quaggin, MD, chief and the Charles H. Mayo, MD, Professor of Medicine in the Division of Nephrology and Hypertension, wrote an editorial published by the American Society of Nephrology.

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like